HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ayanin

has cytoprotective and anti-neuroinflammatory activities; isolated from Croton schiedeanus (Euphorbiaceae); structure in first source

Also Known As:

5,3'-dihydroxy-3,7,4'-trimethoxyflavone

Networked: 4 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrans: 130
    - Benzopyrans: 195
      - Chromones: 159
        Flavonoids: 9773
        ayanin: 4
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzopyrans: 195
      - Chromones: 159
        Flavonoids: 9773
        ayanin: 4

Experts

1.	Chen, Chi-Ming: 2 articles (06/2010 - 10/2008)
2.	Ko, Wun-Chang: 2 articles (06/2010 - 10/2008)
3.	Chen, Chien-Ming: 1 article (06/2010)
4.	Lee, Fei-Peng: 1 article (06/2010)
5.	Shen, Hsin-Yi: 1 article (06/2010)
6.	Shih, Chwen-Ming: 1 article (06/2010)
7.	Chan, Agnes L-F: 1 article (10/2008)
8.	Chien, Hui-Chi: 1 article (10/2008)
9.	Huang, Hui-Lin: 1 article (10/2008)
10.	Lin, Chun-Nan: 1 article (10/2008)

Related Diseases

1.	Cardiovascular Diseases (Cardiovascular Disease) 04/01/2002 - "These results suggest that extracts of Croton schiedeanus, the native south American plant from which ayanin was isolated, might be beneficial in cardiovascular disease."
2.	Asthma (Bronchial Asthma) 06/10/2010 - "In conclusion, the above results suggest that ayanin may have the potential for use in treating allergic asthma." 10/01/2008 - "In the present results, the PDE4(H)/PDE4(L) ratios of quercetin (1), ayanin (3), and QPME (5) were >30, >19, and 11, respectively (Table 1), which are higher than or equal to that of AWD12-281, the selective PDE4 inhibitor with the greatest potential currently undergoing clinical trials for treating asthma and chronic obstructive pulmonary disease."
3.	Chronic Obstructive Pulmonary Disease (COPD) 10/01/2008 - "In the present results, the PDE4(H)/PDE4(L) ratios of quercetin (1), ayanin (3), and QPME (5) were >30, >19, and 11, respectively (Table 1), which are higher than or equal to that of AWD12-281, the selective PDE4 inhibitor with the greatest potential currently undergoing clinical trials for treating asthma and chronic obstructive pulmonary disease."
4.	Vomiting 06/10/2010 - "In the present results, ayanin did not affect xylazine/ketamine-induced anesthesia, suggesting that ayanin has few or no adverse effects, such as nausea, vomiting, and gastric hypersecretion. "
5.	Respiratory Hypersensitivity 06/10/2010 - "Ayanin, a non-selective phosphodiesterase 1-4 inhibitor, effectively suppresses ovalbumin-induced airway hyperresponsiveness without affecting xylazine/ketamine-induced anesthesia."

Related Drugs and Biologics

1.	Phosphodiesterase 4 Inhibitors
2.	Quercetin
3.	Therapeutic Uses
4.	Xylazine (Xylazin)
5.	Phosphoric Diester Hydrolases (Phosphodiesterases)
6.	Peptide Hydrolases (Proteases)
7.	Ovalbumin
8.	Ketamine
9.	Flavonoids

Related Therapies and Procedures

1.	Anesthesia